> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-93/
- Published: 2017-02-26T12:00:00.000Z
- Updated: 2026-09-14T22:08:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138072

**Xynomic Pharmaceuticals** has acquired from **Pharmacyclics** the exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative Pan-Histone Deacetylase Inhibitor designed to target hematological and solid tumors. To date a total of 14 Phase 1 and 2 clinical trials of Abexinostat in U.S., EU and Asia have been completed, demonstrating that Abexinostat is clinically active in multiple tumor settings. Xynomic says it aims to initiate Phase 3 registrational trials worldwide in the third quarter.

**Merck** took a pre-tax $2.9 billion hit on its hepatitis C drug candidate uprifosbuvir due to flagging sales in the market based on the success of drugs already available, presumably **Gilead**’s Harvoni and Sovaldi therapies. Merck acquired the drug in 2014 with its $3.9 billion acquisition of **Idenix Pharmaceuticals**, and it now values the drug at $240 million.

**Henry Schein, Inc.** has entered into an agreement to acquire **Southern Anesthesia & Surgical**, a U.S. distributor of anesthesia and surgical supplies to oral surgeons, dental anesthesiologists, and periodontists. Southern Anasthesia, which offers controlled and non-controlled pharmaceuticals, as well as surgical supplies, to about 11,500 customers, had 2016 sales of $72 million.